On April 9. 2026 Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, reported it will present updated data from its ongoing FIT-001 clinical trial (NCT 06026410) evaluating darlifarnib (KO-2806) in combination with cabozantinib in patients with advanced clear cell renal cell carcinoma at the International Kidney Cancer Symposium (IKCS) Europe 2026 in Paris, France.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The data to be presented build on earlier findings from the FIT-001 study reported at the 2025 European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress, where the combination of darlifarnib and cabozantinib demonstrated encouraging clinical activity and a manageable safety profile in patients with advanced renal cell carcinoma.
IKCS Europe 2026 Presentation Details
Title: Farnesyl transferase inhibitor (FTI) darlifarnib (KO-2806) combined with cabozantinib (cabo) in clear cell renal cell carcinoma (ccRCC) patients after prior exposure to cabo: Preliminary Phase 1 results from FIT-001
Abstract Session: 7
Date: April 17, 2026
Time: 3:30 p.m. – 4:30 p.m. CEST
Virtual Investor Event
Kura will host a webcast and conference call on April 17, 2026, at 7:30 am PT / 10:30 am ET / 4:30 pm CEST featuring management and a clinical investigator from the darlifarnib program. The live webcast and replay will be available on the Company’s website at www.kuraoncology.com under the Investors tab in the Events and Presentations section.
About darlifarnib
Darlifarnib is a next-generation farnesyl transferase inhibitor (FTI) designed to inhibit farnesylation of RHEB and suppress mTORC1 signaling. This mechanism has potential to enhance the activity of multiple targeted therapies, including VEGFR-targeted therapies such as cabozantinib.
(Press release, Kura Oncology, APR 9, 2026, View Source [SID1234664274])